Jared Whitlock (@Jared_Whitlock) profile picture

Jared Whitlock

@Jared_Whitlock

Freelance reporter. Reach out privately on Signal: jaredwhitlock.73

 San Diego
jaredwhitlock.pressfolios.com/
Joined September 2010
  • Tweets2K
  • Following865
  • Followers1.6K
For families, a $2.1M medicine can feel like both a miracle and an out-of-reach reality. Now, biotechs in China are racing to develop lower-cost alternatives: endpoints.news/chinese-biote…
In China, a low-cost push to rival a life-saving, $2M medicine

In China, a low-cost push to rival a life-saving, $2M medicine

Indian veterinarian Nirnay Murthy sought Lantu Biopharma's experimental gene therapy for his son's spinal muscular atrophy after being unable to afford Novartis's $2.1M Zolgensma treatment.

endpoints.news
2
5
1,371
Jared Whitlock retweeted
Bob Herman (@bobjherman) profile picture
Bob Herman@bobjhermanOct 28
“It’s very clear Epic owns the market. Its prices are extraordinary. It has killed innovators left and right — it’s time for a change.” A must-read story from Casey Ross and @brittanytrang, who are investigating the electronic health records giant Epic. statnews.com/2026/10/28/epic…
As Epic’s dominance grows, its iron grip is choking innovation in health technology

As Epic’s dominance grows, its iron grip is choking innovation in health technology

A STAT investigation found that Epic selectively withholds access to patient data, disadvantaging rival software developers and stymying innovation.

statnews.com
23
72
6
306
71,545
A couple paid more than $800,000 for a gene-editing therapy for their daughter. She died, and it wasn’t made public. An exclusive by @bborrell from us and @ScienceMagazine. science.org/content/article/…
Exclusive: Death of girl in Chinese gene-editing trial was never made public

Exclusive: Death of girl in Chinese gene-editing trial was never made public

Parents want accountability after study went disastrously wrong, Science and Retraction Watch investigation reveals

science.org
1
12
1
28
11,956
Jared Whitlock retweeted
Matthew Herper (@matthewherper) profile picture
Matthew Herper
@matthewherperApr 30
Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstood statnews.com/2026/04/30/crai… via @statnews
Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily...

Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily...

J. Craig Venter, the scientist whose relentless ambition helped turn genetics from an artisanal trade into an industrialized information machine, died at 79.

statnews.com
1
11
30
8,621
Jared Whitlock retweeted
Matthew Herper (@matthewherper) profile picture
Matthew Herper
@matthewherperApr 30
I'm sad to learn that J. Craig Venter, a key figure in modern genomics and an inveterate troublemaker, passed away. Craig was very important to the study of human genetics and the biotechnology industry. He also had an impact on my career. The pitch that led @michaelnoer to hire me at Forbes in 2000 was about Venter's company, Celera Genomics, and its work on the mouse genome. Seventeen years, later, Michael edited a cover story I wrote about Venter for Forbes.
Image from Matthew Herper (@matthewherper)
3
24
2
110
18,051
Must read story from @antonioregalado about a biotech that wants to make brainless clones as a personal source of organ donation or even body transplant. They pitched themselves to me as an alternative to animal models company. That wasn't the full story. technologyreview.com/2026/03…
Inside the stealthy startup that pitched brainless human clones

Inside the stealthy startup that pitched brainless human clones

The ultimate plan to live forever is a brand new body.

technologyreview.com
2
6
1,219
Jared Whitlock retweeted
Brent Crane (@bcamcrane) profile picture
Brent Crane@bcamcraneMar 27
Theia Group set out to revolutionize space-based surveillance. Its enigmatic founder, a former NASA engineer, envisioned nothing less then "Google for the physical world," he told me from jail. My @BW investigation into Theia's dramatic rise & fall: bloomberg.com/news/features/…
The Death Spiral of a $250 Million Satellite Startup

The Death Spiral of a $250 Million Satellite Startup

Theia raised big money to launch a next-level network of digital imagery, but its legacy is mostly lawsuits, including federal fraud charges.

bloomberg.com
4
8
1,362
ICYMI: Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans
Image from Jared Whitlock (@Jared_Whitlock)
1
3
15
1,098
Reporting here: endpoints.news/china-is-taki…
Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans

Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans

Chinese firm Belief BioMed launches $350K hemophilia B gene therapy, challenging $3.5M Hemgenix by CSL Behring/uniQure, as China leads global race for cheaper gene therapies.

endpoints.news
1
111
Jared Whitlock retweeted
Drew Armstrong (@ArmstrongDrew) profile picture
Drew Armstrong
@ArmstrongDrewMar 5
China competition is coming for the US's multimillion-dollar gene therapies -- a must-read from @Jared_Whitlock about what's happening there and how it will affect access around the world: endpoints.news/china-is-taki…
Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans

Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans

Chinese firm Belief BioMed launches $350K hemophilia B gene therapy, challenging $3.5M Hemgenix by CSL Behring/uniQure, as China leads global race for cheaper gene therapies.

endpoints.news
4
8
1,930
Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans My latest feature for @endpts, complete with data analysis. endpoints.news/china-is-taki…
Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans

Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans

Chinese firm Belief BioMed launches $350K hemophilia B gene therapy, challenging $3.5M Hemgenix by CSL Behring/uniQure, as China leads global race for cheaper gene therapies.

endpoints.news
3
8
1,600
Jared Whitlock retweeted
John D Carroll (@JohnCendpts) profile picture
John D Carroll
@JohnCendptsMar 3
Did the FDA’s individualized therapy guidance put a spike in the heart of a startup biotech? Fake news, says the HHS. Yeah, it did, says an insider. Exclusive from @RLCscienceboss and @Jared_Whitlock endpoints.news/everyone-medi…
Exclusive: EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway

Exclusive: EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway

EveryOne Medicines, a biotech developing individualized genetic therapies, to close after FDA's new guidance falls short of expectations for streamlined drug approvals.

endpoints.news
4
1
22
7,573
Jared Whitlock retweeted
Jason Mast (@Jasonmmast) profile picture
Jason Mast@JasonmmastMar 3
EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway endpoints.news/everyone-medi…
Exclusive: EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway

Exclusive: EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway

EveryOne Medicines, a biotech developing individualized genetic therapies, to close after FDA's new guidance falls short of expectations for streamlined drug approvals.

endpoints.news
2
6
828
Exclusive: EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway From @RLCscienceboss and me: endpoints.news/everyone-medi…
Exclusive: EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway

Exclusive: EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway

EveryOne Medicines, a biotech developing individualized genetic therapies, to close after FDA's new guidance falls short of expectations for streamlined drug approvals.

endpoints.news
1
2
3
2,766
Jared Whitlock retweeted
Brent Crane (@bcamcrane) profile picture
Brent Crane@bcamcraneFeb 27
Hey everyone! I'm starting a monthly newsletter on @Substack of curated longform journalism recommendations. I'll be highlighting the stories that've stuck with me the most each month + two books & a podcast. 1st post here. Please subscribe and share! open.substack.com/pub/thelon…
1
3
6
330
After rallying, Grail's cancer test faces new uncertainty due to UK study My latest via @endpts: endpoints.news/grails-cancer…
After rallying, Grail's cancer test faces new uncertainty due to UK study

After rallying, Grail's cancer test faces new uncertainty due to UK study

After mounting a comeback with fresh capital and a flashy partnership, cancer testing firm Grail once again faces major questions over the future of its blood test that screens for dozens of cancers.

endpoints.news
1
3
911
A Chinese biotech says its gene therapy slowed aggressive brain cancer in an early human test, but the debated approach is already drawing skepticism from some researchers. My latest. @endpts endpoints.news/neuexcell-the…
Chinese biotech claims promising brain cancer results using debated approach

Chinese biotech claims promising brain cancer results using debated approach

NeuExcell Therapeutics says it slowed an aggressive form of cancer in the first human test of a gene therapy technique that aims to coax the brain into healing itself.

endpoints.news
1
4
1,011
Jared Whitlock retweeted
Lizzy Lawrence (@LizzyLaw_) profile picture
Lizzy Lawrence@LizzyLaw_Feb 18
Honored to have won a George Polk award for my coverage of the turmoil at FDA last year. The STAT team was also recognized for reporting on the Trump admin's impact on health and science. statnews.com/2026/02/18/stat…
STAT wins fourth Polk Award for reporting on impact of Trump on health

STAT wins fourth Polk Award for reporting on impact of Trump on health

STAT has won its fourth Polk Award in five years for documenting the Trump administration’s shakeup of the FDA, scientific research, and public health.

statnews.com
13
12
69
3,201
Jared Whitlock retweeted
Lei Lei Wu (@leilei_wuu) profile picture
Lei Lei Wu@leilei_wuuJan 28
With a valuation of about $61 billion, Hengrui is now larger than Takeda and Bayer. But there’s still one big item on its bucket list: selling its own treatments outside of China. My story in @endpts: endpoints.news/hengrui-blaze…
Can a Chinese drugmaker become a big pharma company? Hengrui is testing the waters

Can a Chinese drugmaker become a big pharma company? Hengrui is testing the waters

With a valuation of about $61.2 billion, Hengrui is now larger than Takeda and Bayer. But there’s still one big item on its bucket list: selling its own treatments outside of China.

endpoints.news
1
4
480
Jared Whitlock retweeted
Endpoints News (@endpts) profile picture
Endpoints News
@endptsJan 14
At #JPM26, pharma leaders said the US should focus on fixing its own biopharma system, not slowing China’s rise in drug development. endpoints.news/jpm26-drugmak…
Drugmakers and investors want US reforms, not to slow down China

Drugmakers and investors want US reforms, not to slow down China

Pfizer CEO Albert Bourla and others at JP Morgan Healthcare Conference advocate for US reforms to compete with China, rather than protectionist measures, amid increased US-China pharma deals.

endpoints.news
2
7
12
2,664
Dispatch from #JPM2026: Drugmakers and investors want US reforms, not to slow down China endpoints.news/jpm26-drugmak…
Drugmakers and investors want US reforms, not to slow down China

Drugmakers and investors want US reforms, not to slow down China

Pfizer CEO Albert Bourla and others at JP Morgan Healthcare Conference advocate for US reforms to compete with China, rather than protectionist measures, amid increased US-China pharma deals.

endpoints.news
3
137
Load more